AP2799A - 1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators - Google Patents

1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators

Info

Publication number: AP2799A
Authority: AP; ARIPO
Prior art keywords: gpr; piperidin; pyrazole derivatives; pyrazole; derivatives
Prior art date: 2009-06-05

Application number

AP2011006020A

Other languages

English (en)

Other versions

AP2011006020A0 (en

Inventor

Michael Paul Deninno

Kentaro Futatsugi

Daniel Wei-Shung Kung

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-05

Filing date

2010-05-27

Publication date

2013-11-30

2010-05-27 Application filed by Pfizer filed Critical Pfizer

2011-12-31 Publication of AP2011006020A0 publication Critical patent/AP2011006020A0/xx

2013-11-30 Application granted granted Critical

2013-11-30 Publication of AP2799A publication Critical patent/AP2799A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AP2011006020A 2009-06-05 2010-05-27 1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators AP2799A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US18435509P	2009-06-05	2009-06-05
US25762109P	2009-11-03	2009-11-03
PCT/IB2010/052377 WO2010140092A1 (en)	2009-06-05	2010-05-27	L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators

Publications (2)

Publication Number	Publication Date
AP2011006020A0 AP2011006020A0 (en)	2011-12-31
AP2799A true AP2799A (en)	2013-11-30

Family

ID=42358441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2011006020A AP2799A (en)	2009-06-05	2010-05-27	1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators

Country Status (33)

Country	Link
US (1)	US20110020460A1 (es)
EP (1)	EP2438051A1 (es)
JP (1)	JP2012528847A (es)
KR (1)	KR20120061063A (es)
CN (1)	CN102459222B (es)
AP (1)	AP2799A (es)
AR (1)	AR076985A1 (es)
AU (1)	AU2010255422B2 (es)
BR (1)	BRPI1014636A2 (es)
CA (1)	CA2764021C (es)
CL (1)	CL2011003085A1 (es)
CO (1)	CO6470897A2 (es)
CR (1)	CR20110623A (es)
CU (1)	CU20110225A7 (es)
DO (1)	DOP2011000371A (es)
EA (1)	EA020106B1 (es)
EC (1)	ECSP11011493A (es)
GE (1)	GEP20135907B (es)
GT (1)	GT201100308A (es)
HN (1)	HN2011003195A (es)
IL (1)	IL216772A0 (es)
MA (1)	MA33334B1 (es)
MX (1)	MX2011013034A (es)
NI (1)	NI201100204A (es)
NZ (1)	NZ596467A (es)
PE (1)	PE20120399A1 (es)
SG (1)	SG175995A1 (es)
SV (1)	SV2011004063A (es)
TN (1)	TN2012000073A1 (es)
TW (1)	TWI411611B (es)
UY (1)	UY32683A (es)
WO (1)	WO2010140092A1 (es)
ZA (1)	ZA201108481B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA201200046A1 (ru)	2009-06-24	2012-08-30	Бёрингер Ингельхайм Интернациональ Гмбх	Новые соединения, фармацевтическая композиция и связанные с ними способы
WO2010149685A1 (en)	2009-06-24	2010-12-29	Boehringer Ingelheim International Gmbh	New compounds, pharmaceutical composition and methods relating thereto
WO2011113947A1 (en)	2010-03-18	2011-09-22	Boehringer Ingelheim International Gmbh	Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CA2792234C (en)	2010-03-19	2014-05-27	Pfizer Inc.	2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
AU2011322117B2 (en)	2010-10-29	2015-01-22	Pfizer Inc.	N1/N2-lactam acetyl-CoA carboxylase inhibitors
AP2013006809A0 (en) *	2010-11-23	2013-04-30	Pfizer	4-(5-cyano-pyrazol-1-YL)-piperidine derivatives asGPR 119 modulators
GEP20166474B (en)	2011-04-22	2016-05-10	Pfizer	Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
CN103958495B (zh)	2011-06-09	2018-06-22	理森制药股份公司	作为gpr-119的调节剂的化合物
CA2841757A1 (en)	2011-07-15	2013-01-24	Etzer Darout	Gpr 119 modulators
BR112014000288A2 (pt)	2011-07-22	2017-01-10	Pfizer	moduladores do receptor de glucagon de quinolinila
JP6043355B2 (ja)	2011-08-31	2016-12-14	ファイザー・インク	ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
BR112014011254A2 (pt)	2011-11-11	2017-05-16	Pfizer	2-tiopirimidinonas
SG11201405477XA (en)	2012-04-06	2014-11-27	Pfizer	Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
US9309232B2 (en) *	2012-04-24	2016-04-12	Board Of Trustees Of Northern Illinois University	Synthesis of novel inhibitors of isoprenoid biosynthesis
EP2852597B1 (en)	2012-05-04	2016-06-08	Pfizer Inc	Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2.
JP2015522080A (ja)	2012-07-11	2015-08-03	エルセリクスセラピューティクスインコーポレイテッド	スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
US9260455B2 (en)	2012-09-20	2016-02-16	Pfizer Inc.	Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2931731A1 (en)	2012-12-11	2015-10-21	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en)	2012-12-19	2016-08-02	Pfizer Inc.	Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (en)	2013-02-13	2017-08-09	Pfizer Inc	Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
ES2665153T3 (es)	2013-10-09	2018-04-24	Pfizer Inc.	Antagonistas del receptor EP3 de prostaglandina
PE20161368A1 (es)	2014-03-17	2016-12-25	Pfizer	Inhibidores de diacilglicerol aciltranferasa 2
ME03599B (me)	2014-04-04	2020-07-20	Pfizer	Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitora irak4
CR20160455A (es)	2014-04-10	2016-12-16	Pfizer	2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
JP2017119628A (ja) *	2014-05-09	2017-07-06	日産化学工業株式会社	置換アゾール化合物及び糖尿病治療薬
WO2016092413A1 (en)	2014-12-10	2016-06-16	Pfizer Inc.	Indole and indazole compounds that activate ampk
JP2017538769A (ja)	2014-12-22	2017-12-28	ファイザー・インク	プロスタグランジンｅｐ３受容体の拮抗薬
SI3265126T1 (sl)	2015-03-03	2021-11-30	Saniona A/S	Formulacija kombinacije tezofenzina in metoprolola
AU2016257179A1 (en)	2015-05-05	2017-11-02	Pfizer Inc.	2-thiopyrimidinones
WO2016193844A1 (en)	2015-05-29	2016-12-08	Pfizer Inc.	Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
CR20170572A (es)	2015-06-17	2018-03-20	Pfizer	Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
WO2016203335A1 (en)	2015-06-18	2016-12-22	Pfizer Inc.	Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017025849A1 (en)	2015-08-13	2017-02-16	Pfizer Inc.	Bicyclic-fused heteroaryl or aryl compounds
AU2016311376B2 (en)	2015-08-27	2018-10-04	Pfizer Inc.	Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
WO2017037567A1 (en)	2015-09-03	2017-03-09	Pfizer Inc.	Regulators of frataxin
WO2017051303A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
WO2017051294A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
WO2017051276A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
ES2871251T3 (es)	2015-12-29	2021-10-28	Pfizer	3-Azabiciclo[3.1.0]Hexanos sustituidos como inhibidores de la cetohexocinasa
US10155766B2 (en)	2016-06-14	2018-12-18	Board Of Trustees Of Northern Illinois University	Pyrazolopyrimidine antibacterial agents
CA3030381A1 (en)	2016-07-14	2018-01-18	Pfizer Inc.	Pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es)	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
WO2019133445A1 (en)	2017-12-28	2019-07-04	Inception Ibd, Inc.	Aminothiazoles as inhibitors of vanin-1
MX2021002428A (es)	2018-08-31	2023-01-02	Pfizer	Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
WO2020102575A1 (en)	2018-11-16	2020-05-22	Inception Ibd, Inc.	Heterocyclic aminothiazoles and uses thereof
ES3039586T3 (en)	2019-05-20	2025-10-22	Pfizer	Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh)	2019-06-28	2021-04-16	美商輝瑞大藥廠	Bckdk抑制劑
CA3144848C (en)	2019-06-28	2023-11-21	Pfizer Inc.	5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TWI771766B (zh)	2019-10-04	2022-07-21	美商輝瑞股份有限公司	二醯基甘油醯基轉移酶２抑制劑
MA58498B1 (fr)	2020-02-07	2024-08-30	Gasherbrum Bio, Inc.	Agonistes hétérocycliques de glp-1
JP2022058085A (ja)	2020-02-24	2022-04-11	ファイザー・インク	ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
RS65929B9 (sr)	2020-06-09	2025-02-28	Pfizer	Spiro jedinjenja kao antagonisti receptora melanokortina 4 i njihova upotreba
WO2023026180A1 (en)	2021-08-26	2023-03-02	Pfizer Inc.	Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
EP4441037A1 (en)	2021-12-01	2024-10-09	Pfizer Inc.	3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
JP2024544021A (ja)	2021-12-06	2024-11-26	ファイザー・インク	メラノコルチン４受容体アンタゴニストおよびそれらの使用
WO2023169456A1 (en)	2022-03-09	2023-09-14	Gasherbrum Bio , Inc.	Heterocyclic glp-1 agonists
US20250250269A1 (en)	2022-04-14	2025-08-07	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
EP4598908A1 (en)	2022-10-07	2025-08-13	Pfizer Inc.	Hsd17b13 inhibitors and/or degraders
AU2023364628A1 (en)	2022-10-18	2025-04-03	Pfizer Inc.	Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024118524A1 (en)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024125602A1 (en)	2022-12-15	2024-06-20	Gasherbrum Bio, Inc.	Salts and solid forms of a compound having glp-1 agonist activity
KR20250117453A (ko)	2022-12-16	2025-08-04	화이자 인코포레이티드	3-플루오로-4-하이드록시벤즈아미드-함유 억제제 및/또는 분해제 및 이의 용도
CN121311466A (zh)	2023-04-14	2026-01-09	辉瑞大药厂	葡萄糖依赖性促胰岛素多肽受体拮抗剂及其用途
WO2025099566A1 (en)	2023-11-08	2025-05-15	Pfizer Inc.	A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid
TW202539633A (zh)	2024-02-01	2025-10-16	美商輝瑞股份有限公司	葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025224599A1 (en)	2024-04-22	2025-10-30	Pfizer Inc.	Pyrrolidine-based glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026013531A1 (en)	2024-07-10	2026-01-15	Pfizer Inc.	Spiro[2.5]octane compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009014910A2 (en) *	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002068388A2 (en)	2001-02-28	2002-09-06	Merck & Co., Inc.	Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2003072547A1 (en)	2002-02-27	2003-09-04	Pfizer Products Inc.	PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS
US20040220170A1 (en)	2003-05-01	2004-11-04	Atkinson Robert N.	Pyrazole-amides and sulfonamides as sodium channel modulators
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en) *	2003-07-14	2009-12-03	Arena Pharmaceuticals,Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
PL2392565T3 (pl)	2003-09-26	2014-08-29	Exelixis Inc	Modulatory c-Met i sposoby stosowania
EP1753766A1 (en)	2004-05-25	2007-02-21	Pfizer Products Inc.	Tetraazabenzo(e)azulene derivatives and analogs thereof
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DOP2006000009A (es) *	2005-01-13	2006-08-15	Arena Pharm Inc	Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
AU2006299091A1 (en) *	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GB0522846D0 (en)	2005-11-09	2005-12-21	Peakdale Molecular Ltd	Process
EP2021014A1 (en) *	2006-05-26	2009-02-11	Brystol-Myers Squibb Company	Sustained release glp-1 receptor modulators
EP2139888A2 (en)	2007-03-28	2010-01-06	Array Biopharma, Inc.	Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors
US8093257B2 (en)	2007-05-04	2012-01-10	Bristol-Myers Squibb Company	[6,5]-bicyclic GPR119 G protein-coupled receptor agonists
CN102007126A (zh)	2008-02-22	2011-04-06	Irm责任有限公司	作为gpr119活性调控剂的化合物和组合物
US20090270404A1 (en) *	2008-03-31	2009-10-29	Metabolex, Inc.	Oxymethylene aryl compounds and uses thereof
EP2311822A4 (en) *	2008-08-01	2011-08-31	Nippon Chemiphar Co	GPR119 AGONIST

2010
- 2010-05-27 CN CN201080024529.7A patent/CN102459222B/zh not_active Expired - Fee Related
- 2010-05-27 MA MA34412A patent/MA33334B1/fr unknown
- 2010-05-27 GE GEAP201012490A patent/GEP20135907B/en unknown
- 2010-05-27 MX MX2011013034A patent/MX2011013034A/es active IP Right Grant
- 2010-05-27 PE PE2011002028A patent/PE20120399A1/es not_active Application Discontinuation
- 2010-05-27 JP JP2012513706A patent/JP2012528847A/ja active Pending
- 2010-05-27 NZ NZ596467A patent/NZ596467A/en not_active IP Right Cessation
- 2010-05-27 EP EP10724593A patent/EP2438051A1/en not_active Withdrawn
- 2010-05-27 AP AP2011006020A patent/AP2799A/xx active
- 2010-05-27 CA CA2764021A patent/CA2764021C/en not_active Expired - Fee Related
- 2010-05-27 EA EA201190280A patent/EA020106B1/ru not_active IP Right Cessation
- 2010-05-27 BR BRPI1014636A patent/BRPI1014636A2/pt not_active IP Right Cessation
- 2010-05-27 SG SG2011082922A patent/SG175995A1/en unknown
- 2010-05-27 WO PCT/IB2010/052377 patent/WO2010140092A1/en not_active Ceased
- 2010-05-27 KR KR1020117028964A patent/KR20120061063A/ko not_active Ceased
- 2010-05-27 AU AU2010255422A patent/AU2010255422B2/en not_active Expired - Fee Related
- 2010-06-02 TW TW099117782A patent/TWI411611B/zh not_active IP Right Cessation
- 2010-06-03 UY UY0001032683A patent/UY32683A/es unknown
- 2010-06-04 US US12/793,938 patent/US20110020460A1/en not_active Abandoned
- 2010-06-04 AR ARP100101987A patent/AR076985A1/es not_active Application Discontinuation
2011
- 2011-11-16 SV SV2011004063A patent/SV2011004063A/es not_active Application Discontinuation
- 2011-11-18 ZA ZA2011/08481A patent/ZA201108481B/en unknown
- 2011-11-18 NI NI201100204A patent/NI201100204A/es unknown
- 2011-11-24 CR CR20110623A patent/CR20110623A/es unknown
- 2011-11-30 EC EC2011011493A patent/ECSP11011493A/es unknown
- 2011-12-01 GT GT201100308A patent/GT201100308A/es unknown
- 2011-12-01 DO DO2011000371A patent/DOP2011000371A/es unknown
- 2011-12-02 CU CU2011000225A patent/CU20110225A7/es unknown
- 2011-12-05 IL IL216772A patent/IL216772A0/en unknown
- 2011-12-05 HN HN2011003195A patent/HN2011003195A/es unknown
- 2011-12-05 CL CL2011003085A patent/CL2011003085A1/es unknown
- 2011-12-15 CO CO11173248A patent/CO6470897A2/es active IP Right Grant
2012
- 2012-02-16 TN TNP2012000073A patent/TN2012000073A1/fr unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009014910A2 (en) *	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders

Also Published As

Publication number	Publication date
HN2011003195A (es)	2013-03-11
EP2438051A1 (en)	2012-04-11
NZ596467A (en)	2014-01-31
AP2011006020A0 (en)	2011-12-31
DOP2011000371A (es)	2012-04-30
EA020106B1 (ru)	2014-08-29
CN102459222A (zh)	2012-05-16
ECSP11011493A (es)	2011-12-30
UY32683A (es)	2011-01-31
SV2011004063A (es)	2012-01-04
CN102459222B (zh)	2014-06-04
JP2012528847A (ja)	2012-11-15
AU2010255422B2 (en)	2014-04-10
CA2764021C (en)	2014-04-22
TW201109314A (en)	2011-03-16
SG175995A1 (en)	2011-12-29
BRPI1014636A2 (pt)	2016-04-05
MA33334B1 (fr)	2012-06-01
WO2010140092A1 (en)	2010-12-09
IL216772A0 (en)	2012-03-01
CO6470897A2 (es)	2012-06-29
CR20110623A (es)	2012-01-04
ZA201108481B (en)	2013-02-27
TN2012000073A1 (fr)	2013-09-19
CA2764021A1 (en)	2010-12-09
US20110020460A1 (en)	2011-01-27
CU20110225A7 (es)	2013-01-30
NI201100204A (es)	2012-05-22
GT201100308A (es)	2013-11-11
AU2010255422A1 (en)	2011-12-22
TWI411611B (zh)	2013-10-11
EA201190280A1 (ru)	2012-09-28
KR20120061063A (ko)	2012-06-12
GEP20135907B (en)	2013-08-12
AR076985A1 (es)	2011-07-20
CL2011003085A1 (es)	2012-09-07
PE20120399A1 (es)	2012-04-24
MX2011013034A (es)	2012-02-08

Publication	Publication Date	Title
AP2799A (en)	2013-11-30	1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators
ZA201105391B (en)	2012-12-27	Fungicidal pyrazoles
ZA201200895B (en)	2012-11-28	Aminopyrazole derivative
ZA201109214B (en)	2012-08-29	Fungicide pyrazole carboxamides derivatives
IL200047A0 (en)	2010-04-15	Pyrazole derivatives as 11-beta-hsd1 inhibitors
PL2336132T3 (pl)	2014-06-30	Pochodne morfolinopuryny
EP2269993A4 (en)	2011-04-20	2-aminoquinazoline DERIVATIVE
IL206576A0 (en)	2010-12-30	Monosebacate of pyrazole derivative
ZA201304282B (en)	2014-08-27	Pyrazole derivative
IL208623A0 (en)	2010-12-30	Cyclopentylacrylamide derivative
ZA201005769B (en)	2011-10-26	Bicycloamine derivative
IL207225A0 (en)	2010-12-30	Indazole derivatives
IL207192A0 (en)	2010-12-30	Substituted heteroarylamide diazepinopyrimidone derivatives
IL207191A0 (en)	2010-12-30	Substituted heteroaylamide oxazepyrimidone derivatives
IL215901A0 (en)	2012-01-31	Substituted piperidines
EP2373313A4 (en)	2012-06-13	SUBSTITUTED PYRAZOL COMPOUNDS
ZA201006992B (en)	2011-06-29	Hydroxyquinoxalinecarboxamide derivative
ZA201108609B (en)	2013-02-27	Substituted piperidines
IL207315A0 (en)	2010-12-30	Piperidine derivative
IL215235A0 (en)	2011-12-29	Pyrazole compound
IL212683A0 (en)	2011-07-31	Biphenylacetamide derivative
EP2351742A4 (en)	2012-03-28	indazole
GB0806744D0 (en)	2008-05-14	Novel pyrazole derivatives
ZA200905235B (en)	2010-05-26	Pyrazole derivatives as 11-beta-hsd1 inhibitors
EP2344472A4 (en)	2012-11-28	ISOCHINOLINONDERIVATE